Anti-Human CD194 Recombinant Antibody_天津卡梅德科技发展有限公司

>>

>>

>>

>

Anti-Human CD194 Recombinant Antibody

Anti-Human CD194 Recombinant Antibody

产品编号

YR1245

别名

科研级 Mogamulizumab ( 莫格利组单抗 ), Anti-CD194 Recombinant Antibody, Research Grade Mogamulizumab

规格

1mg
5mg

DATASHEET MSDS

立即询价加入询价列表大包装定制

产品介绍

Alias	科研级 Mogamulizumab ( 莫格利组单抗 ), Anti-CD194 Recombinant Antibody, Research Grade Mogamulizumab
Catalog Number	YR1245
Molecular Name	Mogamulizumab
CAS Number	1159266-37-1
Target	CD194[Homo sapiens]
Antibody Isotype	IgG1 Kappa
Clonity	Monoclonal
Size	1mg, 5mg
Concentration	1mg/ml
Purity	>95% as determined by SDS-PAGE
Storage Condition	It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
Formulation	PBS, pH7.5
Shipping Condition	Shipped on ice packs.
Background	Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4). The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease. It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL).
Remarks	This product is for research use only.

推荐产品

400-621-6806
614353794
周一至周五 8:30-18:00
0